


BVT-0264

24-Aug-2011

Manumycin B

[UCF1A; N98-1272A]

BVT-0264-M001	1 mg
BVT-0264-M005	5 mg
Formula	C ₂₈ H ₃₄ N ₂ O ₇
MW	510.6
CAS	139023-58-8



Handling / Storage

Shipping	AMBIENT
Short Term Storage	+4°C
Long Term Storage	-20°C

After reconstitution protect from light at -20°C. Protect from light.

Use / Stability

Stable for at least 1 year after receipt when stored at -20°C.

MSDS available at www.adipogen.com or upon request.

Product Specifications

Source/Host	Isolated from <i>Streptomyces parvulus</i> .
Purity	≥98% (HPLC)
Identity	Determined by ¹ H-NMR and UV.
Appearance	Yellow to brown powder.
Solubility	Soluble in DMSO, methanol or chloroform.

Product Description

- Antibiotic.
- Antibacterial. Active against Gram-positive bacteria.
- Rasfarnesyltransferase inhibitor.
- Apoptosis (Caspase-1) inhibitor.
- AChE inhibitor.

WARNING: Intended for research use only. This product is not intended or approved for human, diagnostics, therapeutic or veterinary use. Use of this product for human or animal testing is extremely hazardous and may result in disease, severe injury, or death. **MATERIAL SAFETY DATA:** Review the complete Material Safety Data Sheet before use.

BioViotica Naturstoffe GmbH
c/o Adipogen AG
Schützenstrasse 12
4410 Liestal - Switzerland
TEL +41-61-926-60-40
FAX +41-61-926-60-49
bioviotica@adipogen.com

BioViotica Naturstoffe GmbH
Dransfelder Weg 6
D-37127 Dransfeld
Germany
TEL +49-5502-30-00-08
info@bioviotica.com

For Local Distributors see
www.adipogen.com

Product Specific References

1. New compounds of the manumycin group of antibiotics and a facilitated route for their structure elucidation: I. Sattler, et al.; J. Org. Chem. **58**, 6583 (1993)
2. Identification of ras farnesyltransferase inhibitors by microbial screening: M. Hara, et al.; PNAS **90**, 2281 (1993)
3. TMC-1 A, B, C and D, new antibiotics of the Manumycin group produced by Streptomyces sp.: J. Kohno, et al.; J. Antibiot. **49**, 1212 (1996)
4. EI-1511-3, -5 and EI-1625-2, novel interleukin-1 beta converting enzyme inhibitors produced by Streptomyces sp. E-1511 and E-1625. III. Biochemical properties of EI-1511-3, -5 and EI-1625-2: T. Tanaka, et al.; J. Antibiot. **49**, 1085 (1996)
5. The manumycin-group metabolites: I. Sattler, et al.; Nat. Prod. Rep. **15**, 221 (1998) (Review)
6. The first total synthesis of a type II manumycin antibiotic, (+)-TMC-1 A: the total syntheses of (-)-LL-C10037 β and (+)-manumycin B: J.J. Cronjé Grové, et al.; Chem. Commun. **1999**, 421 (1999)
7. Isolation and characterization of N98-1272 A, B and C, selective acetylcholinesterase inhibitors from metabolites of an actinomycete strain: Z.-H. Zheng, et al.; J. Enzyme Inh. Med. Chem. **22**, 43 (2007)

WARNING: Intended for research use only. This product is not intended or approved for human, diagnostics, therapeutic or veterinary use. Use of this product for human or animal testing is extremely hazardous and may result in disease, severe injury, or death. **MATERIAL SAFETY DATA:** Review the complete Material Safety Data Sheet before use.

BioViotica Naturstoffe GmbH
c/o Adipogen AG
Schützenstrasse 12
4410 Liestal - Switzerland
TEL +41-61-926-60-40
FAX +41-61-926-60-49
bioviotica@adipogen.com

BioViotica Naturstoffe GmbH
Dransfelder Weg 6
D-37127 Dransfeld
Germany
TEL +49-5502-30-00-08
info@bioviotica.com

For Local Distributors see
www.adipogen.com